States that the price of the Elan ProStep nicotine patch which it markets in the U.S. is "within pennies" of the prices of Ciba- Geigy's Habitrol and Alza/Marion Merrell Dow's Nicoderm patches. The company takes issue with a statement in "The Pink Sheet" that ProStep will cost consumers about $4 per day, while the other nicotine patches will cost about $3 per day ("The Pink Sheet" Feb. 3, T&G-2). Ciba-Geigy has revised its estimated price for consumers to around $4 per day, while Marion Merrell Dow maintains that Nicoderm therapy will cost between $3 and $3.50 per day.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth